Ann: Long COVID study identifies diagnostic & therapeutic targets, page-6

Now if the funding is from NIH, it cant be used for DMD.

But that should be enough for confidence in ANP to grow and that dhould help get us over the line with DMD.

Imagine two indications. both with unmet needs being investigated. Thats huge for derisking, and huge for potential income/market cap growth.

We arent there yet. Nothing is a sure thing until a deal is signed. But we are now in a much stronger position than we were prior to this announcement.

We still have combination data to be announced before the end of year. They know the bio markers. They know how ATL1102 works. So I would think they know what kind of results we should get.

And then of course we have the pending DMD approval trial.

This market cap provides incredible value.